Controversies in the treatment of immune thrombocytopenia

Current Opinion in Hematology

Volumn 23, Issue 5, 2016, Pages 479-485

  Cuker, Adam ^a   Cines, Douglas B ^a   Neunert, Cindy E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Immune thrombocytopenia; management; treatment

Indexed keywords

ELTROMBOPAG; RITUXIMAB; ROMIPLOSTIM; IMMUNOSUPPRESSIVE AGENT;

HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; AGE; CLINICAL DECISION MAKING; DISEASE MANAGEMENT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

AGE FACTORS; CLINICAL DECISION-MAKING; DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84977079296     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000270     Document Type: Review

References (35)

1. Rodeghiero F, Ruggeri M. Treatment of immune thrombocytopenia in adults: the role of thrombopoietin receptor agonists. Semin Hematol 2015; 52:16-24.
2. Cuker A, Neunert C. How I treat refractory immune thrombocytopenia. Blood 2016. [Epub ahead of print]
3. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2015; 13:457-464.
4. Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112:4003-4008.
5. Fujisawa K, Iyori H, Ohkawa H, et al. A prospective, randomized trial of conventional, dose-accelerated corticosteroids and intravenous immunoglobulin in children with newly diagnosed idiopathic thrombocytopenic purpura. Int J Hematol 2000; 72:376-383.
6. Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost 2015; 41:395-404.
7. Wei Y, Ji XB, Wang Y, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood 2016; 127:296-302.
8. Bae SH, Ryoo HM, Lee WS, et al. High dose dexamethasone vs. conventional dose prednisolone for adults with immune thrombocytopenia: a prospective multicenter phase III trial. Paper presented at: Annual Meeting of the American Society of Hematology; December 2010; Orlando, FL.
9. Din B, Wang X, Shi Y, Li Y. Long-term effect of high-dose dexamethasone with or without low-dose dexamethasone maintenance in untreated immune thrombocytopenia. Acta Haematol 2015; 133:124-128.
10. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115:2755-2762.
11. Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood 2013; 121:1976-1981.
12. Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol 2016; 172:262-273.
13. Gomez-Almaguer D, Herrera-Rojas MA, Jaime-Pe rez JC, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood 2014; 123:3906-3908.
14. Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient study during 35 years. Am J Hematol 2016; 91:E267-E272.
15. Mahe vas M, Michel M, Godeau B. How we manage immune thrombocytopenia in the elderly. Br J Haematol 2016; 173:844-856.
16. Park YH, Yi HG, Kim CS, et al. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: amulticenter retrospective study. Acta Haematol 2016; 135:162-171.
17. Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2015; 2:e75-e81.
18. Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood 2015; 125:1541-1547.
19. Zwaginga JJ, van der Holt B, Te Boekhorst PA, et al. Multicenter randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. Haematologica 2015; 100:e90-e92.
20. Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:1653-1661.
21. Levy R, Mahevas M, Galicier L, et al. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev 2014; 13:1055-1063.
22. Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013; 122:1946-1953.
23. Provan D, Newland A. Current management of primary immune thrombocytopenia. Adv Ther 2015; 32:875-887.
24. Chalmers S, Tarantino MD. Romiplostim as a treatment for immune thrombocytopenia: a review. J Blood Med 2015; 6:37-44.
25. Gonzalez-Lopez TJ, Alvarez-Roman MT, Pascual C, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol 2015. [Epub ahead of print]
26. Mazza P, Minoia C, Melpignano A, et al. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a 'real life' retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol 2016; 95:239-244.
27. Gonza lez-Porras JR, Mingot-Castellano ME, Andrade MM, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 2015; 169:111-116.
28. Gonza lez-Lo pez TJ, Pascual C, Alvarez-Roman MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015; 90:E40-E43.
29. Bussel JB, Wang X, Lopez A, Eisen M. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim. Hematology 2015. [Epub ahead of print]
30. Carpenedo M, Cantoni S, Coccini V, et al. Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice. Hematol Rep 2015; 7:5673.
31. Cervinek L, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietinreceptor agonists in adults. Int J Hematol 2015; 102:7-11.
32. Cines DB, Gernsheimer T, Wasser J, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol 2015; 102:259-270.
33. Rizvi H, Butler T, Calaminici M, et al. United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings. Br J Haematol 2015; 169:590-594.
34. Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study. Am J Hematol 2015; 90:598-601.
35. Janssens A, Rodeghiero F, Anderson D, et al. Results from a phase IV openlab study evaluating changes in bone marrow morphology in adult immune thrombocytopenia (ITP) patients receiving romiplostim: analysis of the 1-and 2-year cohorts. Blood 2013; 122:2312-12312.